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Abstract: 
A novel series of 5-(4-formyl substituted phenoxy)-3-methyl-1-phenyl-1H-pyrazole-4-carbonitrile (1a-b) based 
penta-substituted pyridine derivatives  4(a–n) was synthesized by piperidine catalyzed cyclocondensation reaction 
through microwave. The newly synthesized compounds were characterized by spectral studies and also by C, H and 
N analyses. The synthesized compounds were tested for their in vitro tuberculosis activity against H37Rv strains 
using rifampicin, isoniazide and ethambutol as the standard drugs. All novel synthesized compounds were tested for 
their in vitro antimalarial activity against P. falciparum strains using quinine and chloroquine as the standard 
drugs. Molecular docking and pharmacokinetic study were carried out for all the targeted compounds. 
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INTRODUCTION: 
Malaria, a mosquito-borne disease, is the most 
critical health evils in the world at the current time 
[1]. Due to malaria approximate 500 million people 
get affected per annum and about 3 million deaths 
happen due to malaria [2-4]. Amongst the four 
Plasmodium parasites, Plasmodium falciparum is 
considered responsible for 95% of deaths [5]. The 
swell of multidrug-resistant Plasmodium falciparum 
has highlighted the urgent need of discovering new 
antimalarial drugs.  
   
In the current scenario tuberculosis (TB) is a serious 
global health problem [6]. Approximately 32 % of 
the overall mankind is infected with TB and every 
year around 2 million people die and 8 million new 
people are detected tuberculosis active [7]. The 
increase of multidrug-resistant TB (MDR-TB) and 
the emergence of extensively drug-resistant TB 
(XDR-TB) pose new challenge for the preclusion [8]. 
Therefore, there is the urgency for the need of novel 
and effective novel drug to treat TB in a shorter 
duration with less toxicity and fewer side effects. 
 
Microwave assisted synthesis is a branch of green 
chemistry that has attained considerable attention in 
recent years. Chemical transformations involved via 
this technique are eco-friendly, pollution free and 
offer high yields together with simplicity in 
processing and handling [9, 10]. The main 
advantages of microwave-assisted synthesis are rate 
accelerations, high selectivity, improved yields, less 
bye products, shorter reaction times, and easier work-
up [11, 12]. 
 
In modern period pyridine derivatives are a very 
important class of compounds which have good 
biological activity due to their pharmacological 
properties. The biologically active cyano pyridine 
moiety is proving to show potent antifungal [13], 
antibacterial [14], anticancer [15] and antimicrobial 
activity [16]. In addition to that substituted 2-amino-
3-cyanopyridine derivatives are known for various 
biological activities, such as anti-microbial [17], anti 
inflammatory [18], potent inhibitor of HIV-1 
integrase [19], anti-inflammatory [20] and 
antimalarial activity [21]. 
 
In continuation of our on-going research on various 
biologically active heterocyclic derivatives [22, 23] 
and potent  biological screening, microwave assisted 
synthesis of novel 2-amino-6-((4-substituted 
phenyl)thio)-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5yl)oxy) substituted phenyl)pyridine-3,5-
dicarbonitrile (4a-n) has been contemplated with the 
view of getting biologically active compounds for 
pharmaceutical applications. 
 
RESULT AND DISCUSSION: 
Chemistry 
The starting material 5-(4-formyl substituted 
phenoxy)-3-methyl-1-phenyl-1H-pyrazole-4-
carbonitrile (1a-b)  was prepared in three  step. In the 
first step Vilsmeier–Haack reaction [24]) of 3-
methyl-1-phenyl-1H-pyrazol-5(4H)-one gives 5-
Chloro-3-methyl-1-phenyl-1H-pyrazole-4-
carbaldehyde. In second step 5-Chloro-3-methyl-1-
phenyl-1H-pyrazole-4-carbaldehyde containing 
aldehyde group is converted to nitirile group [25].  
The final aldehyde 5-(4-formyl substituted phenoxy)-
3-methyl-1-phenyl-1H-pyrazole-4-carbonitrile (1a-b) 
were prepared by nucleophilic displacement of chloro 
group at C5 in 5-chloro-3-methyl-1-phenyl-1H-
pyrazole-4-carbonitrile (1a-b) with substituted 4-
hydroxy benzaldehyde by refluxing in DMF using 
anhydrous K2CO3 as a base. The final compounds 2-
amino-6-((4-substituted phenyl)thio)-4-(4-((4-cyano-
3-methyl-1-phenyl-1H-pyrazol-5 yl) oxy) substituted  
phenyl)pyridine-3,5-dicarbonitrile(4a-n) were 
prepared in good yield (75-90 %) under by 
microwave irradiation by reacting the mixture of  
substituted 5-(4-formyl substituted phenoxy)-3-
methyl-1-phenyl-1H-pyrazole-4-carbonitrile (1a-b),  
malononitrile (2), substituted thiols (3a-g) and 
catalytic amount of piperidine  in  absolute alcohol 
for 8-15min at 350 W. (Table 1). 
 
 
Scheme 1. Synthesis of 2-amino-6-((4-substituted phenyl)thio)-4-(4-((4-cyano-3-methyl-1-phenyl-1H-pyrazol-5 yl) 
oxy) substituted  phenyl)pyridine-3,5-dicarbonitrile derivatives (4a-n) 
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The agreement of target compounds 4(a–n) may 
progress via the initial formation of an intermediate 
afforded by Knoevenagel condensation of a 
substituted pyrazole aldehyde with malononitrile by 
loss of water molecule, which would undergo 
intermolecular cyclisation of another molecule of 
malononitrile driven through the nucleophilic attack 
of thiophenols in presence of piperidine basic 
reaction medium (Scheme 2). 
 
Table 1: Preliminary characterization of synthesized compounds 4a-n. 
 
 
Entry 
 
R 
 
R1 
conventional method Microwave method 
Time (h) Yielda (%) Time (min) Yielda (%) 
4a -H -Cl 1.5 78 09 89 
4b - OCH3 -Cl 2 76 10 87 
4c -H -CH3 1.5 81 12 90 
4d - OCH3 -CH3 2 75 14 88 
4e -H -Br 1.5 69 12 81 
4f - OCH3 -Br 2 68 13 78 
4g -H -F 1.5 74 09 85 
4h - OCH3 -F 2 68 10 81 
4i -H -OH 1.5 66 11 75 
4j - OCH3 -OH 2 60 13 73 
4k -H - OCH3 1.5 63 12 78 
4l - OCH3 - OCH3 2 64 12 75 
4m -H -H 1.5 67 14 88 
4n - OCH3 -H 2 69 14 83 
   aYields of isolated products 
Reaction mechanism 
 
Scheme 2. Plausible mechanistic pathway for the synthesis of pyridine derivatives 4(a–n) 
 
RESULTS AND DISCUSSION: 
1H NMR, FT-IR, 13C NMR, elemental analysis and 
mass spectrometry techniques were used for 
confirmation of newly synthesised compounds. The 
1H NMR spectra of compounds 4a-n showed the 
presence of –CH3 protons (pyrazole ring) as a sharp 
singlet in the range between δ 2.34-2.45 ppm. The 
broad singlet at δ 5.45-5.65 ppm was observed due to 
–NH2 proton. In the range between δ 7.15-7.78 ppm 
the signals (multiplets) appeared for aromatic 
protons. The IR spectrum of compounds 4a-n 
exhibited characteristic absorption band in the range 
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730-771 cm-1 which can be ascribed to the presence 
of thioether linkage. While absorption band in the 
range of 1212-1231 cm-1 was observed for ether 
linkage. The absorption band in the range 3410-3311 
cm-1 may be attributed to asymmetric & symmetric 
stretching of -NH2.The absorption band was  
observed in the range of 1369-1376 cm-1 may be due 
to presence of -CH3 group. The absorption band in 
the range of 2180-2270 cm-1 was observed due to -
C≡N stretching. The mass spectrum of all the 
compounds showed molecular ion peak (M+) 
corresponding to their respective molecular weights, 
which confirmed the chemical structures. 
Biological result 
In vitro antituberculosis activity  
Evaluation of all newly synthesized compounds was 
performed for antituberculosis activity against 
Mycobacterium tuberculosis H37Rv strain. Screening 
of all the synthesized compounds was conducted at 
250 mg.mL-1 by using Lowenstein–Jensen medium 
(conventional method) as described by Rattan (22). 
The observed results are presented in Table 2 in the 
form of %inhibition. The standard drugs rifampicin, 
ethambutol and isoniazid were used for comparison.  
Table 2:  In vitro antituberculosis activity (% inhibition) of compounds (4a-o) against 
M. tuberculosis H37Rv (at concentration 250 mg/mL). 
Entry 
% 
inhibition 
Entry 
% 
inhibition 
4a 97 4j 40 
4b 95 4k 81 
4c 79 4l 72 
4d 64 4m 94 
4e 57 4n 42 
4f 52 Rifampicin 98 
4g 98 Ethambutol 99 
4h 46 Isoniazide 99 
4i 70   
 
Antituberculosis activity of the all compounds 4a–n 
was conducted at 250 µg/mL concentrations against 
Mycobacterium tuberculosis H37Rv strain. 
Compounds 4a (R = 3-H, R1 = 4-Cl), 4b (R = 3-CH3, 
R1 = 4-Cl), 4g (R = 3-H, R1 = 4-F) and 4m (R = 3-H, 
R1 = 4-H) were found to have brilliant activity (i.e. 
97%, 95%, 98% and 94% at 250 µg/mL) against M. 
tuberculosis H37Rv. Remaining all other compounds 
showed medium inhibition against M. tuberculosis 
H37Rv.  
 
In vitro antimalarial activity 
In vitro antimalarial activity of the all novel 
synthesized compounds 7a-n aligned with P. 
falciparum strain was tested using quinine and 
chloroquine as the reference drugs. The consequences 
of the antimalarial screening are communicated as the 
drug concentration resulting in 50% inhibition (IC50) 
of parasite growth and are listed in Table 3.  
Table 3:  In vitro antimalarial activity of derivatives 4a-n 
Entry IC50(μg/mL) Entry IC50(μg/mL) 
4a 0.023 4i 0.20 
4b 0.18 4j 0.59 
4c 0.54 4k 0.042 
4d 1.84 4l 0.98 
4e 0.37 4m 1.58 
4f 0.75 4n 1.65 
4g 0.057 Quinine 0.268 
4h 1.61 Chloroquine 0.020 
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The compounds 4a (R = -H, R1 = 2,4-di Cl), 4g (R = -
H, R1 = 2-CH3), 4k(R = -H, R1 = 2-OCH3), were 
found to have IC50 0.023, 0.057 and 0.042 
respectively. In this antimalarial screening only three 
compounds were found to be are more active against 
P. falciparum. 
 
5. Docking study of compounds 
In silico pharmacokinetic evaluation 
The different pharmacokinetic parameters viz. 
hydrogen bond acceptor (HBA), hydrogen bond 
donor (HBD), rotatable bonds (Rot B), logP, polar 
surface area (PSA) and binding energy s for 
compounds 4a-n are listed in Table-4. These data 
were evaluated by molecule docking server software. 
The synthesized compounds have a high molecular 
weight (≤ 500) as compared to the standard drugs. 
The compounds 4j and 4l showed elevated hydrogen 
bond acceptor (HBA) value while 4i and 4j have a 
high hydrogen bond donor value. The values of 
rotational bond of all synthesized compounds (4a-n) 
are in between 6-9 which is very near to ethambutol. 
All compounds showed higher than logP (≤ 5) values 
and polar surface area then isoniazide and 
ethambutol. 
 
 
In silico molecular docking study 
Molecular interaction for all the ligands was studied 
using molecule docking server software. The 3D 
diagrams Figs 1A-4A show the binding sites of all 
the ligands within the receptor (2B35). Figs. 1B-4B 
show 2D interaction diagram between amino acids 
and compounds that interacted to the active sites 
(amino acids) of receptor (2B35) through like a 
hydrogen bond. We performed molecular docking 
studies of all compounds (4a-n) and 3D presentation 
of the complex between receptor (PDB ID: 2B35). 
Ethambutol and isoniazide were used as the standard 
drugs. The binding energy docking scores are 
presented in Table-3. It is remarkable that all the 
compounds (4a-n) showed binding energy in between 
-6.39 to -8.26 kcal/mol and formed stronger 
complexes with receptor as compared to the standard 
drugs. Compounds 4a, 4b, 4g and 4m showed very 
poor binding energy (-8.22, -8.26, -8.02, and -8.03 
kcal/mol. respectively) which are potently active 
against tuberculosis (Table-2). 
 
 
Table 4: Pharmacokinetic parameters 
Compound 
ID(s) 
Mol.wta HBAb HBDc RotBd logpe PSAf 
Binding 
energyg 
4a 560.02 8 1 6 7.61 162.63 -8.22 
4b 590.05 9 1 7 7.62 171.86 -8.26 
4c 539.61 8 1 6 7.27 162.63 -7.68 
4d 569.63 9 1 7 7.28 171.86 -6.55 
4e 604.48 8 1 6 7.72 162.63 -7.32 
4f 634.50 9 1 7 7.73 171.86 -7.79 
4g 543.57 8 1 6 7.10 162.63 -8.02 
4h 573.60 9 1 7 7.11 171.86 -7.12 
4i 541.58 9 2 6 6.67 182.86 -7.58 
4j 571.60 10 2 7 6.67 192.09 -6.39 
4k 555.61 9 1 7 6.97 171.86 -6.83 
4l 585.63 10 1 8 6.98 181.09 -6.78 
4m 525.58 8 1 6 6.96 162.63 -8.03 
4n 555.61 9 1 7 6.91 171.86 -7.63 
Isoniazide 137.13 4 2 2 0.77 68.01 -5.1 
Ethambutol 204.30 4 4 9 0.48 64.52 -4.5 
 
    a Molecular Weight ≤ 500 (gm/mol) [26],    b Hydrogen Bond Acceptor ≤ 10 [27],        c Hydrogen Bond Donor ≤ 5       
[27],   d Rotatable Bonds ≤ 10 [27] , e logP ≤ 5 [26],       fPolar Surface Area ≤140 A2 [27],    gBinding energy 
          
Experimental section 
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Starting materials were obtained from Spectrochem 
and Sigma Aldrich. The progress of the reactions was 
checked by TLC on aluminum plates coated with 
silica gel 60 F254, 0.25 mm thickness (Merck). The 
developed chromatograms were visualized under UV 
light. FT-IR spectra were recorded in KBr on a 
Perkin -Elmer Spectrum GX FT-IR 
Spectrophotometer (Perkin-Elmer, USA). The 1H 
NMR and 13C NMR spectra were recorded on a 
Bruker Avance 400. Tetramethylsilane (TMS) was 
used as the internal standard and CDCl3 as the 
solvent. Chemical shifts are reported in parts per 
million (ppm). Melting points are uncorrected and 
were determined using µThermoCal10 melting point 
apparatus (Analab Scientific Pvt. Ltd, India). The 
elemental analysis was performed on Perkin- Elmer 
2400 series-II elemental analyzer (Perkin- Elmer, 
USA) at (SICART), Vallabh Vidyanagar, India .Mass 
spectra were recorded on Shimadzu LCMS 2010 
spectrometer (Shimadzu, Tokyo, Japan) at Sardar 
Patel University (PURSE programme of DST), 
Vallabh Vidyanagar. 
 
 
 
 
 
 
               Fig.1 (A) 3D presentation of the complex between receptor (2B35) and 4a. 
                         (B) Schematic 2D diagram of interaction between active site residues and 4a. 
 
 
 
 
                     Fig.2 (A) 3D presentation of the complex between receptor (2B35) and 4b. 
(B) Schematic 2D diagram of interaction between active site residues and 4b. 
A B 
A B 
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           Fig.3 (A) 3D presentation of the complex between receptor (2B35) and 4g. 
                   (B) Schematic 2D diagram of interaction between active site residues and 4g. 
 
 
 
                Fig.4 (A) 3D presentation of the complex between receptor (2B35) and 4m. 
                          (B) Schematic 2D diagram of interaction between active site residues and 4m. 
General procedure for the microwave promoted 
novel penta- substituted pyridine nucleus with 
pyrazole  
Substituted pyrazole aldehyde (1(a-b), 1 mmol), 
malononitrile (2, 2 mmol), substituted thiophenols 
(3(a-g), 1 mmol) and catalytic amount of piperidine 
were mixed carefully in the ethanol. The reaction 
mixture was heated in microwave oven for 9-14 min 
at 350 W. After cooling to room temperature the final 
products (4a-n) were filtered and crystallized from 
ethanol. 
2-amino-6-((4-chlorophenyl)thio)-4-(4-((4-cyano-3-
methyl-1-phenyl-1H-pyrazol-5-yl)oxy)-
phenyl)pyridine-3,5-dicarbonitrile (4a) 
White solid; yield: 78%; mp 180-183 ºC; IR (KBr, 
νmax, cm-1) = 3430 & 3352 (asym. & sym. stretching 
of –NH2); 2209 (-C≡N stretching), 1374 (-CH3 str.), 
1231 (C-O-C str.), 761 (C-S-C str.), 3010 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.39 (s, 
3H,Pyrazole -CH3), 5.58 (s, 2H, –NH2), 7.15-7.73 (m, 
13H, Ar-H); 13C NMR (100 MHz DMSO-d6) δ: 
13.46, 78.88, 88.60, 96.60, 112.35, 113.49, 115.04, 
121.40, 121.96, 124.05, 125.55, 128.15, 130.15, 
130.64, 133.30, 136.56, 138.09, 139.01, 145.20, 
151.23, 152.59, 157.90, 159.30, 168.60, LC-MS: 
560.03 (M)+; Anal.Calc. For C30H18ClN7OS: 
Elemental Analysis: C, 64.34; H, 3.24; N, 17.51; 
Observed, C, 64.40; H, 3.64; N, 17.93 %. 
 
2-amino-6-((4-chlorophenyl)thio)-4-(4-((4-cyano-3-
methyl-1-phenyl-1H-pyrazol-5-yl)oxy)-3-
methoxyphenyl)pyridine-3,5-dicarbonitrile (4b) 
White solid; yield: 80%; mp 175-177 ºC; IR (KBr, 
νmax, cm-1) = 3454 & 3331 (asym. & sym. stretching 
of –NH2); 2199 (-C≡N stretching), 1370 (-CH3 str.), 
A B 
A B 
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1214 (C-O-C str.), 730 (C-S-C str.), 3018 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.37 (s, 
3H,Pyrazole -CH3), 3.93(s, 3H, -OCH3 ) 5.65 (s, 2H, 
–NH2), 7.17-7.75 (m, 13H, Ar-H); 13C NMR (100 
MHz DMSO-d6) δ: 13.43, 56.41, 78.83, 87.53, 95.65, 
111.45, 113.49, 114.53, 114.84, 121.60, 121.99, 
123.03, 125.43, 128.05, 129.25, 129.65, 132.31, 
136.56, 136.99, 137.11, 144.49, 151.23, 151.55, 
153.60, 156.91, 159.28, 168.67, LC-MS:  590.06 
(M)+ ; Anal.Calc. For C31H20ClN7O2S; Elemental 
Analysis: C, 63.10; H, 3.42; N, 16.62; Observed, C, 
62.80; H, 3.23; N, 16.14 %. 
2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)phenyl)-6-(p-tolylthio)pyri- dine-
3,5-dicarbonitrile (4c) 
White solid; yield: 84; mp 165-167 ºC IR (KBr, 
νmax, cm-1) = 3419 & 3315 (asym. & sym. stretching 
of –NH2); 2180 (-C≡N stretching), 1369 (-CH3 str.), 
1226 (C-O-C str.), 769 (C-S-C str.), 3015 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.35 (s, 
3H,Pyrazole -CH3), 2.36 (s, 3H, -CH3), 5.45 (s, 2H, –
NH2), 7.18-7.56 (m, 13H, Ar-H);   13C NMR (100 
MHz DMSO-d6) δ: 13.55, 21.45, 81.63, 87.04, 95.47, 
111.46, 114.71, 114.98, 115.04, 118.28, 122.92, 
123.40, 128.50, 129.47, 130.20, 130.46, 130.95, 
135.67, 136.59, 140.39, 151.80, 152.07, 156.59, 
159.32,169.73; LC-MS: 539.62 (M)+; Anal.Calc. For 
C31H21N7OS; Elemental Analysis: C, 69.00; H, 3.92; 
N, 18.17; Observed, C, 68.67; H, 3.85; N, 17.97 %. 
2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)-3-methoxy- phenyl)-6-(p-
tolylthio)pyridine-3,5-dicarbonitrile (4d) 
White solid; yield: 83; mp 156-160 ºC; IR (KBr, 
νmax, cm-1) = 3445 & 3335 (asym. & sym. stretching 
of –NH2); 2194 (-C≡N stretching), 1375 (-CH3 str.), 
1219 (C-O-C str.), 752 (C-S-C str.), 3012 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.34(s, 3H, CH3), 
2.36 (s, 3H,Pyrazole -CH3), 3.91(s, 3H, -OCH3 ), 5.48 
(s, 2H, –NH2), 7.17-7.74 (m, 13H, Ar-H); 13C NMR 
(100 MHz DMSO-d6) δ: 13.58, 21.47, 56.45, 82.03, 
86.59, 97.14, 112.40, 113.91, 114.90, 115.14, 119.08, 
122.45, 123.85, 127.10, 129.49, 130.27, 131.01, 
132.25, 134.43, 135.50, 140.19 140.397, 143.81, 
151.40, 152.47, 157.54, 160.02, 168.99 ; LC-MS:  
569.64 (M)+ ; Anal.Calc. For C32H23N7O2S; 
Elemental Analysis: C, 67.47; H, 4.07; N, 17.21; 
Observed, C, 67.30; H, 3.88; N, 17.04 %. 
2-amino-6-((4-bromophenyl)thio)-4-(4-((4-cyano-
3-methyl-1-phenyl-1H-pyra-zol-5-yl)oxy)- 
phenyl)pyridine-3,5-dicarbonitrile (4e) 
White solid; yield: 89; mp 190-194 ºC; IR (KBr, 
νmax, cm-1) = 3418 & 3333 (asym. & sym. stretching 
of –NH2); 2295 (-C≡N stretching), 1372 (-CH3 str.), 
1220 (C-O-C str.), 742 (C-S-C str.), 2990 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.35 (s, 
3H,Pyrazole -CH3), 5.46 (s, 2H, –NH2), 7.19-7.78 (m, 
13H, Ar-H); 13C NMR (100 MHz DMSO-d6) δ: 
12.96, 76.70, 85.10, 95.59, 111.15, 114.41, 115.04, 
120.10, 121.6, 125.15, 126.50, 129.11, 130.05, 
131.45, 132.24, 137.58, 139.15, 140.52, 146.15, 
15.03, 152.64, 157.55, 159.54, 169.02; LC-MS: 
604.49 (M)+; Anal.Calc. For C30H18BrN7OS; 
Elemental Analysis: C, 59.61; H, 3.00; N, 16.22; 
Observed, C, 59.29; H, 2.88; N, 15.98 %. 
2-amino-6-((4-bromophenyl)thio)-4-(4-((4-cyano-
3-methyl-1-phenyl-1H-pyra-zol-5-yl)oxy)-3-
methoxyphenyl)pyridine-3,5-dicarbonitrile (4f) 
White solid; yield: 79; mp 169-173 ºC; IR (KBr, 
νmax, cm-1) = 3442 & 3351 (asym. & sym. stretching 
of –NH2); 2215 (-C≡N stretching), 1374 (-CH3 str.), 
1222 (C-O-C str.), 764 (C-S-C str.), 3005 (Ar-C-H);  
1H NMR (400 MHz, DMSO-d6) δ = 2.39 (s, 
3H,Pyrazole -CH3), 3.94(s, 3H, -OCH3 ) 5.67 (s, 2H, 
–NH2), 7.15-7.72 (m, 13H, Ar-H); 13C NMR (100 
MHz DMSO-d6) δ: 13.43, 56.41, 78.82, 87.54, 95.63, 
111.45, 113.50, 114.52, 114.83, 121.59, 121.98, 
123.03, 124.84, 126.09, 128.05, 129.25, 132.31, 
132.60, 136.99, 137.30, 144.49, 151.23, 151.55, 
153.61, 156.9, 159.30, 168.48;  LC-MS:  634.51 
(M)+ ; Anal.Calc. For C31H20BrN7O2S; Elemental 
Analysis: C, 58.68; H, 3.18; N, 15.45; Observed, C, 
58.54; H, 2.97; N, 15.19 %. 
2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)phenyl)-6-((4-fluoro-phen -yl) 
thio)pyridine-3,5-dicarbonitrile (4g) 
White solid; yield: 85; mp 192-195 ºC IR (KBr, 
νmax, cm-1) = 3458 & 3342 (asym. & sym. stretching 
of –NH2); 2211 (-C≡N stretching), 1375 (-CH3 str.), 
1213 (C-O-C str.), 738 (C-S-C str.), 3011 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.45 (s, 
3H,Pyrazole -CH3), 5.55 (s, 2H, –NH2), 7.17-7.62 (m, 
13H, Ar-H);13C NMR (100 MHz DMSO-d6) δ: 13.56, 
81.63, 87.04, 95.47, 111.46, 114.71, 115.04, 118.28, 
122.92, 123.40, 128.50, 129.29, 129.47, 129.63, 
133.33, 136.91, 139.11, 147.49, 151.28, 151.55, 
153.60, 156.91, 160.28, 167.47; LC-MS: 543.58 
(M)+ ; Anal.Calc. For C30H18FN7OS; Elemental 
Analysis: C, 66.29; H, 3.34; N, 18.04; Observed, C, 
66.01; H, 3.21; N, 17.85 %. 
2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)-3-methoxy- phenyl)-6-((4-
fluorophenyl) thio) pyridine-3,5-dicarbonitrile 
(4h) 
White solid; yield: 84; mp 210-213 ºC; IR (KBr, 
νmax, cm-1) = 3420 & 3347 (asym. & sym. stretching 
of –NH2); 2208 (-C≡N stretching), 1376(-CH3 str.), 
1215 (C-O-C str.), 752 (C-S-C str.), 2979 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.34 (s, 
3H,Pyrazole -CH3), 3.90 (s, 3H, -OCH3 ) 5.60 (s, 2H, 
–NH2), 7.19-7.77 (m, 13H, Ar-H); 13C NMR (100 
MHz DMSO-d6) δ: 14.03, 57.01, 78.93, 89.25, 98.05, 
112.41, 113.99, 114.03, 115.74, 120.28, 121.09, 
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123.03, 124.83, 127.45, 129.25, 131.45, 132.81, 
135.91, 136.54, 137.82, 143.67, 151.57, 152.51, 
154.29, 156.82, 160.21, 168.60; LC-MS: 534.64 
(M)+ ; Anal.Calc. For C31H20FN7O2S; Elemental 
Analysis: C, 64.91; H, 3.51; N, 17.09; Observed, C, 
64.79; H, 3.47; N, 16.86 %. 
2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)phenyl)-6-((4-hydroxy 
phenyl)thio) pyridine-3,5-dicarbonitrile (4i) 
White solid; yield: 81; mp 209-211 ºC; IR (KBr, 
νmax, cm-1) = 3438 & 3311 (asym. & sym. stretching 
of –NH2); 2299 (-C≡N stretching), 1372 (-CH3 str.), 
1223 (C-O-C str.), 771 (C-S-C str.), 3019 (Ar-C-H);  
1H NMR (400 MHz, DMSO-d6) δ = 2.40 (s, 3H, 
Pyrazole  -CH3), 5.66 (s, 2H, –NH2), 7.16-7.72 (m, 
13H, Ar-H), 9.24 (s, 1H, -OH); 13C NMR (100 MHz 
DMSO-d6) δ: 14.04, 82.61, 87.14, 94.97, 112.41, 
114.76, 115.54, 119.59, 122.49, 125.41, 129.80, 
129.99, 130.05, 130.48, 132.30, 137.51, 139.11, 
148.19, 151.28, 152.05, 153.40, 157.51, 161.18, 
167.59; LC-MS: 541.59 (M)+; Anal.Calc.: 
C30H19N7O2S For; Elemental Analysis: C, 66.53; H, 
3.54; N, 18.10; Observed, C, 66.45; H, 3.19; N, 17.94 
%. 
2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)-3-methoxy- phenyl)-6-((4-
hydroxyphenyl) thio)pyridine-3,5-dicarbonitrile 
(4j) 
White solid; yield: 90 mp 222-225 ºC; IR (KBr, 
νmax, cm-1) = 3452 & 3337 (asym. & sym. stretching 
of –NH2); 2208 (-C≡N stretching), 1371 (-CH3 str.), 
1224 (C-O-C str.), 765 (C-S-C str.), 2983 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.38 (s, 
3H,Pyrazole -CH3), 3.92 (s, 3H, -OCH3 ) 5.64 (s, 2H, 
–NH2), 7.18-7.73 (m, 13H, Ar-H), 9.25 (s, 1H, -OH);  
13C NMR (100 MHz DMSO-d6) δ: 14.07, 56.49, 
78.88, 87.40, 95.40, 112.45, 113.94, 114.54, 115.58, 
120.19, 121.49, 123.53, 126.17, 129.13, 129.95, 
130.48, 131.58, 135.43, 136.90, 137.01, 140.19, 
152.53, 153.50, 153.80, 156.82, 159.58, 168.98; LC-
MS: 571.62 (M)+ ; Anal.Calc. C31H21N7O3S : For; 
Elemental Analysis: C, 65.14; H, 3.70; N, 17.15; 
Observed, C, 64.99; H, 4.06; N, 17.01 %. 
 2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)phenyl)-6-((4-methoxy 
phenyl)thio)pyridine-3,5-dicarbonitrile (4k) 
White solid; yield: 83; mp 218-221 ºC; IR (KBr, 
νmax, cm-1) = 3421 & 3330 (asym. & sym. stretching 
of –NH2); 2270 (-C≡N stretching), 1375 (-CH3 str.), 
1220 (C-O-C str.), 747 (C-S-C str.), 3005 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.35 (s, 
3H,Pyrazole -CH3), 3.91 (s, 3H, –OCH3 ), 5.59 (s, 2H, 
–NH2), 7.20-7.72 (m, 13H, Ar-H); 13C NMR (100 
MHz DMSO-d6) δ: 13.58, 21.46, 81.59, 88.05, 
969.21, 112.40, 113.54, 114.90, 115.54, 117.24, 
121.42, 123.40, 128.80, 129.07, 130.46, 130.46, 
131.64, 134.15, 136.9, 144.51, 152.59, 158.07, 
155.49, 160.12,169.75; LC-MS: 555.62 (M)+ ; 
Anal.Calc. C31H21N7O2S: For; Elemental Analysis: C, 
67.01; H, 3.81; N, 17.65; Observed, C, 66.91; H, 
3.57; N, 17.43 %. 
2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)-3-methoxy- phenyl)-6-((4-
methoxyphenyl) thio)pyridine-3,5-dicarbonitrile 
(4l) 
White solid; yield: 79; mp 220-223 ºC; IR (KBr, 
νmax, cm-1) = 3410 & 3312 (asym. & sym. stretching 
of –NH2); 2189 (-C≡N stretching), 1370 (-CH3 str.), 
1222 (C-O-C str.), 721 (C-S-C str.), 2999 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.34 (s, 
3H,Pyrazole -CH3), 3.88 (s, 3H, –OCH3 ), 3.93 (s, 3H, 
–OCH3 ), 5.57 (s, 2H, –NH2), 7.19-7.70 (m, 13H, Ar-
H); 13C NMR (100 MHz DMSO-d6) δ: 14.05, 22.14, 
57.25, 83.17, 86.50, 97.84, 111.10, 113.91, 114.95, 
114.54, 118.88, 122.49, 125.05, 128.84, 129.79, 
130.47, 131.91, 132.05, 133.43, 138.00, 141.51 
142.97, 143.01, 151.40, 153.94, 159.04, 160.09, 
167.48 ;  LC-MS: 585.64 (M)+ ; Anal.Calc. 
C32H23N7O3S: For Elemental Analysis: C, 65.63; H, 
3.96; N, 16.74; Observed, C, 65.48; H, 3.76; N, 16.57 
%. 
2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)phenyl)-6- (phenyl thio) 
pyridine-3,5-dicarbonitrile (4m) 
White solid; yield: 80; mp 219-222 ºC; IR (KBr, 
νmax, cm-1) = 3441 & 3324 (asym. & sym. stretching 
of –NH2); 2212 (-C≡N stretching), 1375 (-CH3 str.), 
1212 (C-O-C str.), 749 (C-S-C str.), 3007 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.37 (s, 3H, 
Pyrazole  -CH3), 5.58 (s, 2H, -NH2), 7.17-7.71 (m, 
9H, -Ar-H), 13C NMR (100 MHz DMSO-d6) δ: 
13.60, 81.85, 87.15, 99.69, 112.58, 113.91, 116.81, 
119.18, 122.92, 124.50, 129.45, 129.99, 130.47, 
130.69, 132.13, 138.51, 139.01, 149.45, 150.27, 
151.55, 154.40, 157.61, 162.08, 168.57; LC-MS: 
525.59 (M)+ ; Anal.Calc. C30H19N7OS: For; 
Elemental Analysis: C, 68.56; H, 3.64; N, 18.66; 
Observed, C, 65.48; H, 3.47; N, 18.48 %. 
 2-amino-4-(4-((4-cyano-3-methyl-1-phenyl-1H-
pyrazol-5-yl)oxy)-3-methoxy- phenyl)-6-
(phenylthio)pyridine-3,5-dicarbonitrile (4n) 
White solid; yield: 90; mp 227-230 ºC; IR (KBr, 
νmax, cm-1) = 3430 & 3320 (asym. & sym. stretching 
of –NH2); 2182 (C≡N stretching), 1374 (-CH3 str.), 
1219 (C-O-C str.), 751 (C-S-C str.), 2987 (Ar-C-H); 
1H NMR (400 MHz, DMSO-d6) δ = 2.35 (s, 
3H,Pyrazole -CH3), 3.90 (s, 3H, –OCH3 ), 5.61 (s, 2H, 
–NH2), 7.15-7.73 (m, 13H, Ar-H); 13C NMR (100 
MHz DMSO-d6) δ: 13.45, 56.42, 78.83, 87.26, 95.52, 
111.46, 113.52, 114.71, 114.97, 121.61, 121.95, 
123.03, 127.02, 125.06, 129.26, 129.39, 130.02, 
132.46, 135.79, 136.98, 144.41, 151.19, 151.55, 
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153.63, 156.83, 159.31, 169.26,;  LC-MS: 555.62 
(M)+; Anal.Calc. C31H21N7O2S: For; Elemental 
Analysis: C, 67.01; H, 3.81; N, 17.65; Observed, C, 
66.66; H, 3.64; N, 17.48 %. 
 
CONCLUSION: 
A highly sustainable and efficient multicomponent 
synthesis of novel penta- substituted pyridine bearing 
a pyraozle scaffolds under microwave irradiation is 
reported. The notable features of this methodology 
are eco-friendly reaction conditions, no side product, 
the avoidance of toxic catalysts and easy purification. 
Amongst the all novel tested compounds 4a, 4g and 
4k showed more potent antimalarial activities against 
P. falciparum Compounds 4a, 4b, 4g and 4m have 
shown brilliant anti tuberculosis activity against 
Mycobacterium tuberculosis H37Rv strains as well 
as very poor binding energy in molecule docking 
study as compared to isoniazide and ethambutol. 
Compounds 4a and 4g are more potent against both 
activity viz. antimalarial and antituberculosis. 
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